Related Experiment Video
Updated: Jun 2, 2026
07:29
Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
Published on: June 20, 2015
Metformin allergy.
1Wiwanitkit House, Bangkhae, Bangkok, Thailand 101 60.
Indian Journal of Pharmacology
|May 17, 2011
Summary
Metformin, a common diabetes medication, can rarely cause allergic reactions. This report details a specific case where a patient developed skin lesions due to metformin allergy.
Area of Science:
- Endocrinology
- Dermatology
- Pharmacology
Background:
- Metformin is a first-line oral antihyperglycemic agent for type 2 diabetes mellitus.
- Its efficacy and safety profile are well-established, making it a cornerstone of diabetes management.
- Adverse drug reactions, though uncommon, necessitate thorough investigation and reporting.
Purpose of the Study:
- To report a rare case of metformin allergy.
- To highlight the dermatological manifestations of this adverse drug reaction.
- To increase awareness among clinicians regarding potential allergic responses to metformin.
Main Methods:
- A case study approach was employed.
- Clinical presentation, including detailed skin lesion description, was documented.
- Diagnostic considerations for drug-induced hypersensitivity were evaluated.
Main Results:
- The patient exhibited characteristic skin lesions consistent with an allergic reaction.
- Metformin was identified as the likely causative agent.
- The reaction resolved upon discontinuation of metformin.
Conclusions:
- Metformin allergy, while infrequent, can manifest with significant dermatological symptoms.
- Clinicians should consider metformin hypersensitivity in diabetic patients presenting with unexplained skin lesions.
- Prompt recognition and management are crucial for patient safety and treatment adherence.
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:29Hyperglycemia
Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:15Hypoglycemia and Glucagon
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...